390 related articles for article (PubMed ID: 30922997)
1. Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial.
Lucendo AJ; Miehlke S; Schlag C; Vieth M; von Arnim U; Molina-Infante J; Hartmann D; Bredenoord AJ; Ciriza de Los Rios C; Schubert S; Brückner S; Madisch A; Hayat J; Tack J; Attwood S; Mueller R; Greinwald R; Schoepfer A; Straumann A;
Gastroenterology; 2019 Jul; 157(1):74-86.e15. PubMed ID: 30922997
[TBL] [Abstract][Full Text] [Related]
2. Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.
Straumann A; Lucendo AJ; Miehlke S; Vieth M; Schlag C; Biedermann L; Vaquero CS; Ciriza de Los Rios C; Schmoecker C; Madisch A; Hruz P; Hayat J; von Arnim U; Bredenoord AJ; Schubert S; Mueller R; Greinwald R; Schoepfer A; Attwood S;
Gastroenterology; 2020 Nov; 159(5):1672-1685.e5. PubMed ID: 32721437
[TBL] [Abstract][Full Text] [Related]
3. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.
Dellon ES; Katzka DA; Collins MH; Hamdani M; Gupta SK; Hirano I;
Gastroenterology; 2017 Mar; 152(4):776-786.e5. PubMed ID: 27889574
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.
Dellon ES; Woosley JT; Arrington A; McGee SJ; Covington J; Moist SE; Gebhart JH; Tylicki AE; Shoyoye SO; Martin CF; Galanko JA; Baron JA; Shaheen NJ
Gastroenterology; 2019 Jul; 157(1):65-73.e5. PubMed ID: 30872104
[TBL] [Abstract][Full Text] [Related]
5. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis.
Straumann A; Conus S; Degen L; Frei C; Bussmann C; Beglinger C; Schoepfer A; Simon HU
Clin Gastroenterol Hepatol; 2011 May; 9(5):400-9.e1. PubMed ID: 21277394
[TBL] [Abstract][Full Text] [Related]
6. Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6-week open-label trial of the EOS-2 Programme.
Miehlke S; Schlag C; Lucendo AJ; Biedermann L; Vaquero CS; Schmoecker C; Hayat J; Hruz P; Ciriza de Los Rios C; Bredenoord AJ; Vieth M; Schoepfer A; Attwood S; Mueller R; Burrack S; Greinwald R; Straumann A;
United European Gastroenterol J; 2022 Apr; 10(3):330-343. PubMed ID: 35412032
[TBL] [Abstract][Full Text] [Related]
7. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis.
Miehlke S; Hruz P; Vieth M; Bussmann C; von Arnim U; Bajbouj M; Schlag C; Madisch A; Fibbe C; Wittenburg H; Allescher HD; Reinshagen M; Schubert S; Tack J; Müller M; Krummenerl P; Arts J; Mueller R; Dilger K; Greinwald R; Straumann A
Gut; 2016 Mar; 65(3):390-9. PubMed ID: 25792708
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Budesonide Oral Suspension Maintenance Therapy in Patients With Eosinophilic Esophagitis.
Dellon ES; Katzka DA; Collins MH; Gupta SK; Lan L; Williams J; Hirano I
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):666-673.e8. PubMed ID: 29902649
[TBL] [Abstract][Full Text] [Related]
9. Novel corticosteroid formulations in the treatment of eosinophilic esophagitis: what is the evidence?
Walgraeve S; Vanuytsel T
Acta Gastroenterol Belg; 2023; 86(3):437-448. PubMed ID: 37814560
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis.
Hirano I; Dellon ES; Hamilton JD; Collins MH; Peterson K; Chehade M; Schoepfer AM; Safroneeva E; Rothenberg ME; Falk GW; Assouline-Dayan Y; Zhao Q; Chen Z; Swanson BN; Pirozzi G; Mannent L; Graham NMH; Akinlade B; Stahl N; Yancopoulos GD; Radin A
Gastroenterology; 2020 Jan; 158(1):111-122.e10. PubMed ID: 31593702
[TBL] [Abstract][Full Text] [Related]
11. Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real-world efficacy from the EoE CONNECT registry.
Laserna-Mendieta EJ; Navarro P; Casabona-Francés S; Savarino EV; Amorena E; Pérez-Martínez I; Guagnozzi D; Blas-Jhon L; Betoré E; Guardiola-Arévalo A; Pellegatta G; Krarup AL; Perello A; Barrio J; Gutiérrez-Junquera C; Teruel Sánchez-Vegazo C; Fernández-Fernández S; Naves JE; Oliva S; Rodríguez-Oballe JA; Carrión S; Espina S; Llorente Barrio M; Masiques-Mas ML; Dainese R; Feo-Ortega S; Martín-Dominguez V; Fernández-Pacheco J; Pérez-Fernández MT; Ghisa M; Maniero D; Nantes-Castillejo Ó; Nicolay-Maneru J; Suárez A; Maray I; Llerena-Castro R; Ortega-Larrodé A; Alcedo J; Granja Navacerrada A; Racca F; Santander C; Arias Á; Lucendo AJ;
United European Gastroenterol J; 2024 Jun; 12(5):585-595. PubMed ID: 38284792
[TBL] [Abstract][Full Text] [Related]
12. Budesonide Oral Suspension Significantly Improves Eosinophilic Esophagitis Histology Scoring System Results: Analyses From a 12-Week, Phase 2, Randomized, Placebo-controlled Trial.
Collins MH; Dellon ES; Katzka DA; Hirano I; Williams J; Lan L
Am J Surg Pathol; 2019 Nov; 43(11):1501-1509. PubMed ID: 31498177
[TBL] [Abstract][Full Text] [Related]
13. Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.
Hirano I; Collins MH; Katzka DA; Mukkada VA; Falk GW; Morey R; Desai NK; Lan L; Williams J; Dellon ES;
Clin Gastroenterol Hepatol; 2022 Mar; 20(3):525-534.e10. PubMed ID: 33887475
[TBL] [Abstract][Full Text] [Related]
14. Topical steroids in eosinophilic esophagitis: Systematic review and meta-analysis of placebo-controlled randomized clinical trials.
Murali AR; Gupta A; Attar BM; Ravi V; Koduru P
J Gastroenterol Hepatol; 2016 Jun; 31(6):1111-9. PubMed ID: 26699695
[TBL] [Abstract][Full Text] [Related]
15. RPC4046, a Monoclonal Antibody Against IL13, Reduces Histologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis.
Hirano I; Collins MH; Assouline-Dayan Y; Evans L; Gupta S; Schoepfer AM; Straumann A; Safroneeva E; Grimm M; Smith H; Tompkins CA; Woo A; Peach R; Frohna P; Gujrathi S; Penenberg DN; Li C; Opiteck GJ; Olson A; Aranda R; Rothenberg ME; Dellon ES;
Gastroenterology; 2019 Feb; 156(3):592-603.e10. PubMed ID: 30395812
[TBL] [Abstract][Full Text] [Related]
16. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis.
Alexander JA; Jung KW; Arora AS; Enders F; Katzka DA; Kephardt GM; Kita H; Kryzer LA; Romero Y; Smyrk TC; Talley NJ
Clin Gastroenterol Hepatol; 2012 Jul; 10(7):742-749.e1. PubMed ID: 22475741
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis.
Gupta SK; Vitanza JM; Collins MH
Clin Gastroenterol Hepatol; 2015 Jan; 13(1):66-76.e3. PubMed ID: 24907502
[TBL] [Abstract][Full Text] [Related]
18. Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.
Dellon ES; Collins MH; Katzka DA; Hudgens S; Lan L; Williams J; Vera-Llonch M; Hirano I
Clin Gastroenterol Hepatol; 2021 Apr; 19(4):699-706.e4. PubMed ID: 32272243
[TBL] [Abstract][Full Text] [Related]
19. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.
Dohil R; Newbury R; Fox L; Bastian J; Aceves S
Gastroenterology; 2010 Aug; 139(2):418-29. PubMed ID: 20457157
[TBL] [Abstract][Full Text] [Related]
20. Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial.
Dellon ES; Lucendo AJ; Schlag C; Schoepfer AM; Falk GW; Eagle G; Nezamis J; Comer GM; Knoop K; Hirano I
Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2485-2494.e15. PubMed ID: 35181572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
